ViaSat Stock Gets Barclays Upgrade as Cash Flow Break-Even Approaches
Barclays lifts ViaSat rating, price target $49. Satellite biz strong, cash burn ending, big launch soon, may sell spectrum.
Barclays lifts ViaSat rating, price target $49. Satellite biz strong, cash burn ending, big launch soon, may sell spectrum.
Plus Therapeutics’ REYOBIQ gets FDA orphan drug status for rare kids’ brain tumors.
Bed Bath & Beyond is buying F9 Brands to offer cabinets, flooring & more, making home projects easier with one-stop shopping.
ANI Pharma shares jump as it launches FDA-approved generic Monoket to prevent chest pain from heart disease.
Exxon Mobil says Middle East conflict cut 6% output; LNG damage hits supply, but higher prices may boost profits later.
Oscar Health CEO bought $11.9M in shares after stock payout, showing strong confidence. Shares jumped.